208 related articles for article (PubMed ID: 11399947)
21. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
22. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
23. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
[TBL] [Abstract][Full Text] [Related]
24. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Ann Oncol; 2013 May; 24(5):1225-31. PubMed ID: 23230137
[TBL] [Abstract][Full Text] [Related]
25. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
26. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.
Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Altorjai G; Locker GJ; Mader R; Zielinski CC; Steger GG
BMC Cancer; 2006 Mar; 6():81. PubMed ID: 16563172
[TBL] [Abstract][Full Text] [Related]
29. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
30. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
31. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
32. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type.
Agrawal AK; Jelen M; Rudnicki J; Grzebieniak Z; Zyśko D; Kielan W; Słonina J; Marek G
Folia Histochem Cytobiol; 2010 Jan; 48(1):26-9. PubMed ID: 20529812
[TBL] [Abstract][Full Text] [Related]
33. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
34. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.
Moazzezy N; Farahany TZ; Oloomi M; Bouzari S
Asian Pac J Cancer Prev; 2014; 15(4):1685-8. PubMed ID: 24641390
[TBL] [Abstract][Full Text] [Related]
35. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
36. Cancer associated serum antigen (CASA) levels in patients with breast carcinoma and in 3 control groups without breast cancer.
Meisel M; Weise J; Schwesinger G; Straube W
Arch Gynecol Obstet; 1998; 261(3):159-62. PubMed ID: 9651660
[TBL] [Abstract][Full Text] [Related]
37. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
Barrenetxea G; Schneider J; Llorente MF
Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
[No Abstract] [Full Text] [Related]
38. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
van Dalen A
Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
[TBL] [Abstract][Full Text] [Related]
39. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study.
Kurebayashi J; Nishimura R; Tanaka K; Kohno N; Kurosumi M; Moriya T; Ogawa Y; Taguchi T
Breast Cancer; 2004; 11(4):389-95. PubMed ID: 15604995
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
Lumachi F; Brandes AA; Ermani M; Bruno G; Boccagni P
Anticancer Res; 2000; 20(6C):4751-5. PubMed ID: 11205212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
